Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Intangibles (2021 - 2025)

Barinthus Biotherapeutics' Intangibles history spans 5 years, with the latest figure at $14.3 million for Q4 2025.

  • For Q4 2025, Intangibles fell 34.9% year-over-year to $14.3 million; the TTM value through Dec 2025 reached $14.3 million, down 34.9%, while the annual FY2025 figure was $14.3 million, 34.9% down from the prior year.
  • Intangibles reached $14.3 million in Q4 2025 per BRNS's latest filing, down from $14.9 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $31.4 million in Q4 2021 to a low of $14.3 million in Q4 2025.
  • Average Intangibles over 5 years is $24.6 million, with a median of $25.1 million recorded in 2023.
  • Peak YoY movement for Intangibles: decreased 10.06% in 2022, then plummeted 34.9% in 2025.
  • A 5-year view of Intangibles shows it stood at $31.4 million in 2021, then fell by 10.06% to $28.3 million in 2022, then fell by 11.18% to $25.1 million in 2023, then fell by 12.59% to $21.9 million in 2024, then plummeted by 34.9% to $14.3 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Intangibles are $14.3 million (Q4 2025), $14.9 million (Q3 2025), and $20.4 million (Q2 2025).